Kemp, Karen
Avery, Pearl
Bryant, Ruby
Cross, Amanda
Danter, Kayleigh
Kneebone, Andrew
Morris, Deborah
Walker, Amy
Whitley, Lisa
Dibley, Lesley
Funding for this research was provided by:
Takeda UK Ltd (20039, 20039)
Article History
Received: 21 December 2022
Accepted: 18 October 2023
First Online: 2 November 2023
Declarations
:
: The study was approved by the Ethics Committee at the University of Greenwich London (Ref: 20.1.5.5). All participants provided voluntary informed consent prior to data collection, and all methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable – no identifiable data is reported in this study.
: AVERY: speaker fees from Tillotts, Pharma Dr Falk, Ferring, and MD education. DIBLEY: speaker fees from Abbvie, Dr Falk, Ferring, Janssen and WedMD; funding to support research from Takeda and Janssen. KEMP: speaker fees from Abbvie, Dr Falk, Ferring, Janssen, MSD, Takeda, Tillotts, Shield. WHITLEY: speaker fees from Fresenius Kabi, Advisory board- Galapagos, conference sponsorship from Janssen and Pharmacosmos. BRYANT, CROSS, DANTER, KNEEBONE, MORRIS, WALKER: No competing interests to declare.